Pfizer

$Pfizer(PFE.US)

Context: Seeing Moderna leverage OpenAI and generative AI to accelerate its mRNA clinical pipeline made me re-evaluate legacy pharma. Pfizer has been heavily integrating AI through platforms like “Charlie” and partnerships with CytoReason to compress drug discovery timelines and cut R&D overhead. With Pfizer’s oncology push and compressed valuation post-COVID, AI efficiency could significantly improve long-term trial success rates and margins.

My trade: Opened a position. The risk-to-reward ratio looks attractive given the low valuation multiples, solid dividend yield, and underappreciated AI-driven R&D pipeline optimization compared to pure biotech peers.

Takeaway: Next time, I will scale in using smaller dollar-cost averaging tranches rather than opening a full starter position all at once to navigate sector volatility.

@Captain's Watch

$Pfizer(PFE.US)Pfizer has been showing signs of a strong recovery, climbing toward US$28 as markets rotate into defensive healthcare names. Its improving earnings outlook, recurring cash flow, attractive dividend and pipeline developments continue to support the stock.

As expected preferred to secure the some gain and moving on to the next opportunity during rebound

Watching Pfizer can hold above the support level and break through resistance.

Keeping an eye on earnings recovery, oncology and vaccine pipeline developments, dividend strength and broader defensive sector rotation

Drug pricing pressure, pipeline execution and slower than expected revenue growth could weigh on the stock

Keeping an eye on the bank earnings, the US jobs report, and any updates on the Strait of Hormuz. This week could influence market sentiment across financials, tech, and energy, so volatility may create both risks and opportunities for investors.

Everyone is still in shock right now. Once bitten by a snake, ten years afraid of a rope.

Fed’s Schmid sees AI capex fuelling inflation. Provoking thought: if AI forces higher-for-longer rates, could the technology driving productivity today become the catalyst behind tomorrow’s valuation reset?

Michael Burry says the stock market is "near a major top, and we could see a drop similar to 1987." Do you agree?

My opinion : Most major markets are trading close to record highs now, except HK stock market. Future gains will have to come mainly from earnings growth and not from valuations that are getting more expensive now.

Invest carefully or look to gold or REITs as an alternative.😆

It has been a good response from the market since the lows last week. It held those lows and is making higher highs on the smaller timeframes. Encouraging indeed.

Really one of a kind company. But at current valuations, might be better off to wait for the unlocking of shares to come through first.

even with cash injection. the stock price still unable to hold or goes up. earning is still a question for both companies.